Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITCA 650 cardiovascular outcomes study in type 2 diabetes
2012-002219-25Phase 3Completed
- Sponsor
- Intarcia Therapeutics
- Start
- Jan 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) comparing ITCA 650 plus standard of care with Control plus standard of care (2 arms). Started Jan 2013; status: completed.
02
Drugs
ITCA 650exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-002219-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002219-25.